Paper Details

  1. Home
  2. Paper Details

S-Adenosylmethionine Inhibits Cell Growth and Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c and MiRNA-449a.

Author: CacciapuotiGiovanna, CaragliaMichele, CoppolaAlessandra, IlissoConcetta Paola, MoscaLaura, PorcelliMarina, SchiraldiChiara, StellavatoAntonietta

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Triple-negative breast cancer (TNBC) is a particularly aggressive type of breast cancer. This study investigates the potential of S-adenosyl-L-methionine (AdoMet) as a treatment for TNBC. AdoMet was found to increase the expression of certain microRNAs (miRNAs) that have anti-cancer effects, suggesting that AdoMet may be a promising treatment for TNBC.
Paper Details　
Original Abstract of the Article :
Triple-negative breast cancer (TNBC) is one of the most common malignancies worldwide and shows maximum invasiveness and a high risk of metastasis. Recently, many natural compounds have been highlighted as a valuable source of new and less toxic drugs to enhance breast cancer therapy. Among them, S-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795242/

データ提供：米国国立医学図書館（NLM）

AdoMet: A Promising Weapon Against Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC), a particularly aggressive type of breast cancer, presents a formidable challenge for medical researchers. The search for effective and less toxic treatments is an ongoing quest, with natural compounds emerging as potential solutions. This research explores the anti-cancer properties of S-adenosyl-L-methionine (AdoMet) in TNBC cells, specifically examining its impact on miRNA expression and cell growth. This study is like venturing into a hidden valley in the desert of cancer research, searching for new weapons to combat this formidable foe.

AdoMet Shows Potential as a TNBC Treatment

The study found that AdoMet effectively inhibits the growth and migration of TNBC cells by upregulating specific microRNAs. This discovery is like finding a hidden spring in the desert, offering a new source of hope for those battling TNBC. This suggests that AdoMet could be a valuable addition to the arsenal of TNBC treatments.

A New Era of TNBC Treatment

This research emphasizes the potential of natural compounds in targeting specific pathways involved in cancer development. It encourages a focus on personalized medicine, tailoring treatments to the unique characteristics of each patient's cancer. Think of it as a journey through the desert of cancer research, where we need to find the best combination of resources to navigate the challenges.

Dr.Camel's Conclusion

This study provides a promising glimpse into the potential of AdoMet as a treatment for TNBC. It underscores the importance of exploring natural compounds and understanding the complex interplay of microRNAs in cancer development.

Date :
  1. Date Completed 2021-09-13
  2. Date Revised 2021-09-13
Further Info :

Pubmed ID

33396625

DOI: Digital Object Identifier

PMC7795242

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.